EUK Fundamental Analysis - EUKEDOS SPA

Fundamental Rating

Overall EUK gets a fundamental rating of 1 out of 10. We evaluated EUK against 33 industry peers in the Health Care Providers & Services industry. EUK has a medium profitability rating, but doesn't score so well on its financial health evaluation. EUK has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EUK has reported negative net income.

EUK had a positive operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: EUK reported negative net income in multiple years.

Each year in the past 5 years EUK had a positive operating cash flow.

1.2 Ratios

The Return On Assets of EUK (-0.65%) is worse than 81.82% of its industry peers.

Looking at the Return On Equity, with a value of -3.97%, EUK is doing worse than 81.82% of the companies in the same industry.

The Return On Invested Capital of EUK (2.64%) is worse than 72.73% of its industry peers.

Measured over the past 3 years, the Average Return On Invested Capital for EUK is below the industry average of 6.56%.

The 3 year average ROIC (2.58%) for EUK is below the current ROIC(2.64%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	-0.65%
ROE	-3.97%
ROIC	2.64%

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

1.3 Margins

The Operating Margin of EUK (9.80%) is better than 90.91% of its industry peers.

EUK's Operating Margin has improved in the last couple of years.

Looking at the Gross Margin, with a value of 95.00%, EUK belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.

EUK's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	9.8%
PM (TTM)	N/A
GM	95%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EUK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

EUK has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for EUK remains at a similar level compared to 5 years ago.

EUK has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.28, we must say that EUK is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of EUK (0.28) is worse than 87.88% of its industry peers.

EUK has a Debt/Equity ratio of 2.94. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of EUK (2.94) is worse than 78.79% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.94
Debt/FCF	N/A
Altman-Z	0.28

ROIC/WACC0.55

WACC4.81%

2.3 Liquidity

EUK has a Current Ratio of 0.32. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of EUK (0.32) is worse than 87.88% of its industry peers.

A Quick Ratio of 0.32 indicates that EUK may have some problems paying its short term obligations.

EUK's Quick ratio of 0.32 is on the low side compared to the rest of the industry. EUK is outperformed by 87.88% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.32
Quick Ratio	0.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EUK have decreased strongly by -260.63% in the last year.

The Revenue has been growing slightly by 4.81% in the past year.

EUK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.94% yearly.

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EUK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

EUK's Enterprise Value to EBITDA ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	9.66

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EUK!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

EUKEDOS SPA

BIT:EUK (12/19/2025, 7:00:00 PM)

0.7

-0.02 (-2.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners1.98%

Ins Owner ChangeN/A

Market Cap15.92M

Revenue(TTM)51.30M

Net Income(TTM)-1.15M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.31
P/FCF	N/A
P/OCF	2.74
P/B	0.55
P/tB	1.79
EV/EBITDA	9.66

EPS(TTM)-0.05

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.67

FCFYN/A

OCF(TTM)0.26

OCFY36.49%

SpS2.26

BVpS1.28

TBVpS0.39

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.65%
ROE	-3.97%
ROCE	3.52%
ROIC	2.64%
ROICexc	2.69%
ROICexgc	3.14%
OM	9.8%
PM (TTM)	N/A
GM	95%
FCFM	N/A

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

ROICexc(3y)2.64%

ROICexc(5y)2.29%

ROICexgc(3y)3.08%

ROICexgc(5y)2.68%

ROCE(3y)3.43%

ROCE(5y)2.97%

ROICexgc growth 3Y-1.81%

ROICexgc growth 5Y0.32%

ROICexc growth 3Y-1.47%

ROICexc growth 5Y0.29%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

F-Score5

Asset Turnover0.29

Health

		Industry Rank	Sector Rank
Debt/Equity	2.94
Debt/FCF	N/A
Debt/EBITDA	7.49
Cap/Depr	328.04%
Cap/Sales	40.87%
Interest Coverage	250
Cash Conversion	50.88%
Profit Quality	N/A
Current Ratio	0.32
Quick Ratio	0.32
Altman-Z	0.28

F-Score5

WACC4.81%

ROIC/WACC0.55

Cap/Depr(3y)160.89%

Cap/Depr(5y)115.09%

Cap/Sales(3y)22.9%

Cap/Sales(5y)16.27%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-10.09%

EBIT growth 3Y3.47%

EBIT growth 5Y2.9%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-480.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-38.86%

OCF growth 3Y20.95%

OCF growth 5Y10.45%

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

ChartMill assigns a fundamental rating of 1 / 10 to EUK.MI.

What is the valuation status of EUKEDOS SPA (EUK.MI) stock?

ChartMill assigns a valuation rating of 0 / 10 to EUKEDOS SPA (EUK.MI). This can be considered as Overvalued.

What is the profitability of EUK stock?

EUKEDOS SPA (EUK.MI) has a profitability rating of 4 / 10.

Can you provide the financial health for EUK stock?

The financial health rating of EUKEDOS SPA (EUK.MI) is 1 / 10.

EUKEDOS SPA (EUK.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

What is the valuation status of EUKEDOS SPA (EUK.MI) stock?

What is the profitability of EUK stock?

Can you provide the financial health for EUK stock?